FY2026 EPS Estimate for Gilead Sciences Decreased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Erste Group Bank decreased their FY2026 earnings estimates for shares of Gilead Sciences in a research note issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will post earnings per share of ($0.75) for the year, down from their prior forecast of ($0.74). The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.50) per share.

A number of other research firms have also recently weighed in on GILD. Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Rothschild & Co Redburn dropped their price target on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Finally, Wall Street Zen downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Trading Up 2.0%

Shares of Gilead Sciences stock opened at $135.77 on Wednesday. The company has a 50-day moving average of $129.61 and a two-hundred day moving average of $136.39. Gilead Sciences has a 12-month low of $108.46 and a 12-month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The stock has a market cap of $168.35 billion, a PE ratio of -50.85 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.01 earnings per share.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 82,000 shares of company stock worth $10,641,790 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently modified their holdings of the company. Paulson Wealth Management Inc. lifted its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. grew its holdings in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. grew its holdings in shares of Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock worth $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC increased its position in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Strong quarterly revenue and underlying performance: Gilead’s second-quarter revenue increased roughly 10% year over year to $7.8 billion, exceeding analyst expectations. Although an $11.2 billion one-time write-off tied to acquired in-process research and development produced a reported loss, the adjusted loss of $6.75 per share was better than the $7.25 consensus estimate. GILD—An Attractive Biotech Stock with Solid Base Revenue Growth
• Positive Sentiment: Pipeline investment continues: Gilead exercised an option under its collaboration with MacroGenics to exclusively license a preclinical bispecific program. The decision triggers a $10 million payment to MacroGenics and adds another potential oncology asset to Gilead’s development portfolio, although the program remains at an early stage. MacroGenics Announces Achievement of $10 Million Milestone
• Positive Sentiment: ADC research collaboration: Gilead is working with Nucleai on AI-powered tissue analysis to support its global antibody-drug conjugate clinical programs. The collaboration could improve biomarker identification and clinical-development decisions, supporting Gilead’s oncology strategy. Nucleai Advances AI-Powered Tissue Intelligence
• Positive Sentiment: Constructive investor sentiment: A recent analysis argued that the market may be underestimating Gilead’s growth potential, while unusually heavy call-option activity indicates increased speculative interest in further gains. Gilead Sciences: The Market May Be Underestimating Its Growth
• Neutral Sentiment: Analyst questions from the earnings call focused on Gilead’s growth strategy, pipeline execution and the outlook following its latest results. Short-interest data showed no meaningful reported short position, but the figures appeared unreliable because both periods listed zero shares.
• Negative Sentiment: Erste Group Bank made a minor reduction to its fiscal 2027 earnings-per-share forecast, lowering it from $9.59 to $9.57. The small revision is a modest negative but does not materially change the earnings outlook. Gilead Sciences Analyst Estimate Update

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.